ArticleEye and vision (London, England)2026
SLC7A11-mediated disulfidptosis underlies the pathogenesis of proliferative diabetic retinopathy.
Article in Eye and vision (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundWe investigated the role of disulfidptosis, a recently identified form of cell death, in the pathogenesis of proliferative diabetic retinopathy (PDR) and explore the function of the cystine/glutamate antiporter, SLC7A11, as a key mediator and potential therapeutic target.
methodsBioinformatic analysis was used to screen disulfidptosis-related genes from public RNA sequencing datasets, which were subsequently validated in PDR fibrovascular membranes (FVMs) and vitreous humor via immunofluorescence and western blotting analysis. Human retinal microvascular endothelial cells (HRMECs) were cultured in normal or high-glucose media, and SLC7A11 expression modulated using small interfering RNA or lentiviral overexpression. Angiogenesis was assessed via proliferation, migration, and tube formation assays. Disulfidptosis was induced via acute glucose deprivation in high-glucose-adapted HRMECs and biochemically evaluated. A streptozotocin-induced diabetic mouse model was utilized to assess SLC7A11 expression in vivo, and therapeutic efficacy was tested through weekly intravitreal lavage with glucose-free versus glucose-replete solutions.
resultsDisulfidptosis-related genes, particularly SLC7A11, were significantly upregulated in PDR FVMs, predominantly localizing to the vascular endothelium. In vitro, high-glucose conditions induced SLC7A11 and vascular endothelial growth factor A expression in HRMECs, thereby promoting proliferation, migration, and tube formation. SLC7A11 knockdown abrogated these pro-angiogenic effects, whereas overexpression exacerbated them. Critically, high-glucose-adapted cells developed a profound dependency on glucose; subsequent acute glucose deprivation triggered rapid cell death, exhibiting classic disulfidptosis features (F-actin collapse), a process that could not be rescued by ferroptosis inhibitors. In the diabetic mouse model, SLC7A11 expression was similarly upregulated in the pathological retinal vasculature. Therapeutic vitreous lavage with a glucose-free solution significantly attenuated the progression of these pathological neovessels.
conclusionsOur results revealed a novel SLC7A11-mediated metabolic vulnerability in PDR. We demonstrated that exploiting this glucose dependency via localized deprivation induces disulfidptosis-like features in neovascular cells, representing a new therapeutic strategy for PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.